Clinical effect of Recombinant Human Endostatin Injection combined with concurrent chemoradiotherapy in treatment of locally advanced nonsmall cell lung cancer
QU Lingfeng1 ZHAO Jingsheng2 LUO Jiashun1#br#
1.School of Medicine,Jishou University,Hu'nan Province,Xiangxi Tujia and Miao Autonomous Prefecture 416000,China;
2.Department of Oncology,the First Affiliated Hospital of Jishou University,Hu'nan Province,Xiangxi Tujia and Miao Autonomous Prefecture 416000,China
Objective To observe the clinical efficacy and safety of Recombinant Human Endostatin Injection combined with concurrent chemoradiotherapy in treatment of locally advanced non-small cell lung cancer.Methods The clinical data of 49 patients with locally advanced non-small cell lung cancer who received radical concurrent chemoradiotherapy in the Department of Oncology,the First Affiliated Hospital of Jishou University from November 2017 to December 2020 were retrospectively analyzed,they were divided into experimental group (23 cases)and control group (26 cases).Experimental group received Recombinant Human Endostatin Injection concurrent chemoradiotherapy,control group received concurrent chemoradiotherapy.The objective response rate,median times of progression-free survival,1-year progression free survival rates,2-year progression free survival rates,median times of overall survival and the incidence of radiation pneumonitis,radiation esophagitis,bone marrow suppression and digestive tract reaction of two groups were compared.Results The objective response rate of experimental group and control group were 52.2% and 69.2%,respectively.There was no significant difference in the objective response rate between the two groups(P>0.05).The median times of progression-free survival in experimental group and control group were 8.50 months and 6.13 months,respectively.There was no significant difference in median times of progression-free survival between the two groups (P>0.05).The 1-year survival rates were 91.3% and 80.8%,the 2-year survival rates were 53.5%and 43.3%,the median times of overall survival were 28.70 months and 21.13 months,respectively.There were no statistically significant differences in the 1-year survival rate,2-year survival rate and median times of overall survival between the two groups (P>0.05).There was no significant difference in the incidence of radiation pneumonitis,radiation esophagitis,bone marrow suppression and digestive tract reaction between the two groups(P>0.05).Conclusion The efficacy and safety of Recombinant Human Endostatin Injection concurrent chemoradio therapy and concurrent chemoradiotherapy are comparable.Whether Recombinant Human Endostatin Injection concurrent chemoradiotherapy can improve the effect of locally advanced non-small cell lung cancer more than concurrent chemoradiotherapy needs further study.